Research
Hormonal
The pathophysiological link between NAFLD and CVD is driven by systemic inflammation, endothelial dysfunction, and atherogenic dyslipidemia (specifically high ApoC3 and small dense LDL) resulting from hepatic fat accumulation and insulin resistance.
Understanding that liver fat drives heart risk through inflammation and bad cholesterol helps explain why lifestyle changes (diet/exercise) that reduce liver fat also protect the heart. It is not just about weight loss, but improving metabolic health.
StrongSupportsVERY_HIGH confidence
In NAFLD, hepatic fat accumulation results from an imbalance between lipid acquisition and lipid disposal... overproduction of VLDL particles initiates a cluster of plasma lipoprotein abnormalities and an atherogenic dyslipidemia... These apolipoprotein-B containing lipoproteins... are mainly involved in the development of atherosclerosis.
Why this rating
Well-established pathophysiological pathways described in detail with multiple citations.
Source
NAFLD and cardiovascular diseases: a clinical review
Philipp Kasper et al. · Clinical Research in Cardiology · 2020
DOI 10.1007/s00392-020-01709-7
narrative_reviewCited 628×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Non-alcoholic fatty liver disease (NAFLD) is independently associated with a significantly increased risk of cardiovascular disease (CVD) morbidity and mortality, particularly in patients with advanced fibrosis or non-alcoholic steatohepatitis (NASH).Good
- NAFLD is associated with an increased risk of cardiac arrhythmias, specifically atrial fibrillation and ventricular arrhythmias, independent of traditional cardiovascular risk factors.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →